Park Avenue Securities LLC Acquires New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Park Avenue Securities LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,591 shares of the biopharmaceutical company’s stock, valued at approximately $261,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cetera Advisor Networks LLC purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $243,000. First Horizon Advisors Inc. increased its stake in Halozyme Therapeutics by 188.8% during the second quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 472 shares during the period. HighMark Wealth Management LLC increased its stake in Halozyme Therapeutics by 1.0% during the second quarter. HighMark Wealth Management LLC now owns 50,190 shares of the biopharmaceutical company’s stock worth $2,208,000 after purchasing an additional 500 shares during the period. Thompson Davis & CO. Inc. purchased a new stake in Halozyme Therapeutics during the second quarter worth about $398,000. Finally, Sheets Smith Investment Management purchased a new stake in Halozyme Therapeutics during the second quarter worth about $510,000. 96.32% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $54.13, for a total value of $541,300.00. Following the completion of the sale, the senior vice president now owns 163,137 shares in the company, valued at $8,830,605.81. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $53.81, for a total value of $269,050.00. Following the completion of the sale, the chief financial officer now owns 4,045 shares in the company, valued at $217,661.45. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $54.13, for a total value of $541,300.00. Following the completion of the sale, the senior vice president now owns 163,137 shares of the company’s stock, valued at approximately $8,830,605.81. The disclosure for this sale can be found here. Insiders sold 85,000 shares of company stock valued at $4,666,350 over the last three months. 2.30% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $51.42 on Tuesday. The stock has a 50 day moving average price of $55.26 and a 200 day moving average price of $48.34. The company has a quick ratio of 5.03, a current ratio of 5.97 and a debt-to-equity ratio of 15.37. The company has a market capitalization of $6.95 billion, a price-to-earnings ratio of 34.51, a price-to-earnings-growth ratio of 0.67 and a beta of 1.23. Halozyme Therapeutics, Inc. has a 52-week low of $31.36 and a 52-week high of $59.46.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last announced its quarterly earnings results on Tuesday, November 8th. The biopharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.21. The firm had revenue of $208.98 million during the quarter, compared to the consensus estimate of $187.87 million. Halozyme Therapeutics had a return on equity of 134.71% and a net margin of 36.37%. Research analysts predict that Halozyme Therapeutics, Inc. will post 2.07 EPS for the current fiscal year.

Analysts Set New Price Targets

HALO has been the topic of a number of recent research reports. Wells Fargo & Company initiated coverage on shares of Halozyme Therapeutics in a research note on Monday, November 28th. They set an “overweight” rating and a $65.00 price target on the stock. SVB Leerink cut their price target on shares of Halozyme Therapeutics from $62.00 to $61.00 and set an “outperform” rating on the stock in a research note on Wednesday, January 11th. StockNews.com initiated coverage on Halozyme Therapeutics in a research report on Wednesday, October 12th. They set a “hold” rating for the company. JPMorgan Chase & Co. boosted their price objective on Halozyme Therapeutics from $53.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 22nd. Finally, Benchmark boosted their price objective on Halozyme Therapeutics from $55.00 to $68.00 and gave the stock a “buy” rating in a research report on Thursday, December 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $59.63.

Halozyme Therapeutics Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.